Outsourced Pharma App Notes & Case Studies

  1. The Past And Future Of Managing Raw Material And Process Risks In Biomanufacturing 9/18/2018

    How far have we come in raw material supply management, and what still needs accomplished to ensure the delivery of safe and effective drugs?

  2. Why Invest In Emerging Markets Now 10/10/2018

    Unexplored and emerging markets are an attractive prospect for biopharma companies looking to expand. But when it comes to ensuring success, what’s the wisest way to invest?

  3. Balancing Stainless, Single-Use, And Continuous Manufacturing 9/21/2018

    Several drivers affect how the appropriate facility design and unit operations for a process are selected, making it imperative to properly evaluate each option. 

  4. Process-Economy Simulation Of mAb Capture Step With Protein A Chromatography Resin 10/10/2018

    Calculation examples that highlight scenarios where the enhanced capacity and alkaline‑stability of MabSelect PrismA can provide process economic benefits to large‑scale mAb processing.

  5. Outsourcing Success Requires Constant Evolution 4/14/2020

    Industry Standard Research explains how Life Science Leader’s CMO Leadership Awards and the corresponding market research data can be used by biopharma companies to make more informed CMO selection decisions and by contract manufacturers to optimize operational and marketing strategies.

  6. Clinical Supply Optimization: Enhanced Service Model Saves Client Time On Supplies 12/26/2019

    The Vice President of manufacturing for a clinical-stage biopharmaceutical company faced an avalanche of work when a reorganization left him without a clinical supply manager. Planning to start 5 new clinical trials in 6 months while managing quality assurance, manufacturing, and supplies for new and ongoing studies, he turned to his Fisher Clinical Services account executive with a simple question: “How am I going to do all that?”

  7. Capacity And Performance Of MabSelect™ PrismA Protein A Chromatography Resin 10/2/2018

    This application note demonstrates the binding capacity of MabSelect PrismA in comparison with its predecessor products for both polyclonal and monoclonal antibodies.

  8. An End-To-End, Semi-Continuous Process For mAb Production 9/22/2019

    See how the different unit operations in a laboratory-scale monoclonal antibody (mAb) process can be connected and integrated into a semi-continuous process.

  9. Comparing Continuous And Batch Processing In Downstream Purification 6/10/2019

    Current state-of-the-art continuous manufacturing technologies are being developed and implemented to manufacture a wide variety of products including monoclonal antibodies, recombinant proteins, and other biological modalities. Though upstream fed batch and perfusion bioreactors unit processes are relatively mature, downstream process unit operations are less mature. In this case study, Catalent compared the productivity of purifications running in batch versus continuous mode.

  10. How Biopharma Is Capitalizing On The Antibody Boom 10/10/2018

    Antibodies continue to dominate. Analyzing the strategies employed by successful players in the field could provide invaluable lessons for those hoping to enter it.